





# Outsourcing in Clinical Trials Europe

Barcelona, Spain

3<sup>rd</sup> & 4<sup>th</sup> May 2023 www.arena-international.com/octeurope

'This event will focus on optimizing strategies to create an operationally efficient, specifically targeted clinical trial'

For the 13th Annual event, our flagship European clinical show will focus on providing delegates with practical takeaways and solutions to their most current operational and outsourcing challenges in clinical trials, this is an event not to be missed.

# 2023 Confirmed Speakers

- Roman Fishchuk, Head of Clinical Trials
   Department, Central City Clinical Hospital,
   Ukraine
- Mariusz Olejniczak, CEO, WPD Pharmaceuticals
- Sonja Weiser, Senior Director Clinical Operations, Insmed
- Marco Salami, Head of Clinical & RWE Outsourcing Management, Chiesi Farmaceutici
- Werner Gladdines, VP, Clinical Development Operations, Immunic Therapeutics
- Ivanna Rosendal, Senior Director, IT Business Partner, Ascendis Pharma
- Ivan Vyshnyvetskyy, President of the Ukrainian Association for Clinical Research, Managing Director Ukraine at FutureMeds
- Estrella Garcia, Senior Director Global Clinical Operations, Almirall
- Silvia Perez Torres, Director, Clinical Quality Compliance, AstraZeneca
- Roel van der Heijde, Facilitator & Trainer, Patient Experience Association
- Daniel McVeigh, Director, Clinical Project Lead, Alexion
- Benoît Marchal, Chief Digital Trust Officer, Partners for Patients, PicAps (NFP)
- Laia Casas, Clinical Project Leader, Noucor Health SA
- Priya Nair, Senior Analyst, GlobalData
- Robert S. Greene, President, Hunger and Thirst
   Foundation
- Michael Zörer, Head of Clinical Operations, VarmX

- Domenico Merante, Therapeutic Area Clinical Lead Nephrology, Rare and Orphan Diseases, CSL Vifor
- Henrik Schou, VP, Global Head Evidence Generation, CSL Vifor
- Begoña Nafria Escalera, Patient Engagement & Research Coordinator, Sant Joan de Deu Barcelona Hospital
- James Rudge, Technical Director, Trajan Scientific and Medical
- Balint Feher, Senior Clinical Research Manager,
   Geistlich Pharma AG
- Stephen Lutsch, Former Director Revolutionize Clinical Trials (ReCT), LEO Pharma
- Joana Claverol, Clinical Research Unit Manager, Sant Joan de Deu Barcelona Hospital
- Laura Jiménez Robledo, Clinical Project and Innovation Manager, Novo Nordisk
- Smruthi Panyam, Director, Clinical Data Informatics, BeiGene
- Elena Carzana, Vendors Alliance Manager DM&Stat, Chiesi Farmaceutici
- Anna Pugnetti, Global Clinical and RWE Outsourcing Manager, Chiesi Farmaceutici
- John Zibert, Chief Medical Officer, Coegin Pharma AB
- Stefania Alvino, Digital Orchestrator & Omnichannel Marketing Manager, Daiichi Sankyo
- Orlando Vergara, Barcelona Health Hub Ambassador, former Novartis Neuroscience Head
- Caoimhe Vallely-Gilroy, Independent Advisor HIRANI, former Global Head of Digital Health & Therapeutics at Healthcare Business

- Mateusz Zabolski, Head of Technology Biosamples, AstraZeneca
- Kateryna Orlovska, Country Clinical Quality Management Lead Ukraine, Georgia and CIS, Merck
- Sverre Bengtsson, Co-Founder, Senior Vice President Strategic Relations, Viedoc
- Ana Moreno, Director Global Clinical Operations, APICES
- Gilyana Borlikova, Data Science Manager, ICON
  plc
- Raquel Reviejo, EU Regional Submission Lead, MSD, Sermes CRO

- Neil Vivian, Senior Director of Business Solutions and Product Manager, Anju Software
- Kevin Landells, Vice President, Business Head of IRT,
   IQVIA Technologies
- Karen Maduschke, Senior Director and GM, Patient Consent, IQVIA Technologies

# Outsourcing in Clinical Trials Europe Barcelona Spain 3rd-4th May 2023

# DAY ONE - WEDNESDAY 3RD MAY 2023

7	Metallia 200	No. of the second secon		
STATE STATE OF THE PARTY OF THE	07:45	Conference registration and refreshments		
	08:20	Chair's opening remarks  Chair: Robert S. Greene, President, Hunger and Thirst Foundation		
	08:30	<ul> <li>KEYNOTE Disaster Preparedness: How can the clinical trial industry prepare for the unexpected? Using the Ukrainian crisis as a case study</li> <li>Briefly explaining the impact of the war on Ukraine's/Europe's clinical trial industry</li> <li>Involving sites with sponsor decisions when developing Decentralized models – what tech and solutions can sites offer?</li> <li>Identifying what protocol changes help sites vs what makes their job harder</li> <li>A message to Ukrainian Pharma offices: Importance of backup plans to ensure data integrity and keep trials moving</li> <li>Mitigation risk plans: Making plans for the future and involving all clinical trial stakeholders</li> <li>New solutions – bringing in a reliable Ukrainian CRO with local knowledge to work directly with trial sponsors</li> <li>Roman Fishchuk, Head of Clinical Trials Department, Central City Clinical Hospital, Ukraine</li> </ul>		
The second secon	09:00	Leveraging DCT Technology to Pair Objective and Subjective Patient Data for Improved Outcomes  What does it take to create a more holistic view of the patient journey in clinical trials? Hybrid and decentralizing solutions can bring clinical trials to any patient who is interested and provide more flexible choices for how they participate. By utilizing sensors (objective data) in conjunction with ePROs (subjective data), sponsors and sites can diversify study enrollment, improve patient satisfaction and retention, and increase the generalizability of study findings. Join Joseph Lovett, Solution Specialist at Medidata, for this session to learn more about how you can expand choice for patients in DCTs to benefit both patients and study staff, including what DCT technologies will reduce vs. increase burden.  • Learning Objectives:  • Learn about the methodology of incorporating technology that benefits all stakeholders  • Understand the different types of objective and subjective data capture (manual, automated, and direct) in DCTs  • Discover how to utilize diverse technologies to gather better and more relevant patient data  Joseph Lovett Solution Specialist, Patient Cloud - Medidata, Dassault Systemes		
	09:30	INTERACTIVE SESSION  The Diversity Conversation – follow up from the 2022 discussion and what we should do for and beyond		



Sales Enquiry Nicholas McCudden Head of Sponsorship Sales T: +44 (0)207 9472755
E: NicholasMcCudden@arena-international.com

- How can we improve engagement by paying more of a focus on race and socioeconomic disparities?
- Exploring the role of patient advocacy groups in tackling underrepresentation
- Highlighting the impact on your trial if all groups aren't adequately represented ask ourselves why
- Brainstorming solutions: What actions can we take now to get groups interested in participating in trials?
- Audience stories, feedback and strategies moving forward

Robert S. Greene, President, Hunger and Thirst Foundation & Roel van der Heijde, Facilitator & Trainer, Roel Rotterdam & Patient Experience Association

Advancements in AI: turning big data into actionable intel for optimal site identification

Despite advancing technologies, trials still struggle to meet patient enrolment goals. Slow enrolment directly impacts schedule and budget, with each day of delay carrying cripplingly high costs. Successful, timely patient recruitment is directly linked to effective site selection. Conversely, selecting the wrong site can negatively impact recruitment or result in total failure to enroll patients.

10:00

Join us to learn how advancements in AI can help the pharma industry identify the best sites for their clinical trials through the harnessing of big data. Topics include:

- Transitioning from data overload to data driven decision-making
- The role of Artificial Intelligence in optimizing site identification and selection
- Expected and unexpected downstream benefits of an Al-enabled site selection strategy

Gilyana Borlikova, Data Science Manager, ICON plc

10:30 Morning refreshments and networking

> Stream A: **Outsourcing & Clinical** Operations Chair: Robert S. Greene, President, Hunger and Thirst **Foundation**

Stream B: Clinical Technology & Innovation Chair: Priya Nair, Senior Analyst, GlobalData

Stream C: Clinical Data; Strategy & Planning Chair: Roel van der Heijde, Facilitator & Trainer, Roel Rotterdam & Patient Experience Association



#### PANEL DISCUSSION

Handling prolonged site startup times and the worldwide site staff shortages crisis

- Pinpointing the challenges of getting all vendors/systems in place for study start-up -is this beyond the site's capacity?
- Encouraging all stakeholders to take time and get involved in budget negotiation to reduce site activation delays
- With complexity of trials increasing, what affect will this have on site staff training?
- Importance of easy access to training particularly when site staff is low - can vendors help?

#### PANEL DISCUSSION

Key considerations for designing and implementing DCTs; exploring the protocol design

- Exploring the idea that DCT is not a one-size-fits-all approach
- Looking to outsource if you lack internal capabilities to operationalize DCT
- Designing a proactive strategy with patient groups to maximize efficiency and the patient experience
- Considering a hybrid trial as a more agile design
- Importance of engaging with regulatory agencies early



Data Access vs Data Privacy. Would the simplest not be to ask the patients themselves?

In this talk Benoît will introduce PicAps (Patient in Control, Anonymity Privacy Secured) and explore the benefits of a direct anonymous communication with the patients.

- For what? Clinical trials use cases: Lay summaries, Recruitment, Clinical trial data sharing, long time follow-up, home delivery, continuous monitoring ...
- How it works: decentralized network of

11:00

Sales Enquiry

Head of Sponsorship Sales T: +44 (0)207 9472755 E: NicholasMcCudden@arenainternational.com



- Sharing ideas for retaining site staff/physician talent in the industry
- Could flying study nurses help in the short term?

Moderator: Robert S. Greene, President, Hunger and Thirst **Foundation** 

Panellists: Sonja Weiser, Senior Director Clinical Operations, Insmed:

Roman Fishchuk, Head of Clinical trials department, Central City Clinical Hospital, Ukraine; Ivan Vyshnyvetskyy, President, **Ukrainian Association for** Clinical Research

- Using the knowledge of traditional sites - how to work with a combination of physical and remote sites for protocol design
- Explore user testing and involvement when going digital

Moderator: Priya Nair, Senior Analyst, GlobalData

Panellists: John Zibert, Chief Medical Officer, Coegin Pharma

Stephen Lutsch, Former Director - Revolutionize Clinical Trials (ReCT), LEO Pharma

trusted neutral organizations to ensure privacy

- Regulatory aspect
- The big picture: access to EHR data

Benoît Marchal, Chief Digital Trust Officer, Partners for Patients, PicAps

## **Optimizing Cell-based Gene** Therapy Programs Through the **Continued Evolution**

- Lessons across therapeutic areas
- Driving success in either unexplored settings or in saturated market settings
- Context-dependent stakeholder engagement

11:45 Amy Raymond, PhD, PMP Worldwide Clinical Trials

Therapeutic Strategy Lead, Gene Therapy Think Tank

## Hybrid trials using DCT technology and processes; focus on patients and the sites

- Highlighting the complexity that Hybrid/DCT brings whilst moving away from the common brick-andmortar sites.
- Discussing the rise in regulator concerns in areas such as investigator oversight, and participant's safety when face to face contact is limited.
- How we tend to focus too much on technology when it's actually the processes for the patients and the sites that matter even more.
- Major points to consider in designing hybrid/DCT trials; building blocks and practical examples to best prepare you to meet the needs of regulators whilst keeping the patient and sites front of mind.

Sverre Bengtsson, Co-Founder, Senior Vice President Strategic Relations, Viedoc

## Patient Engagement and eConsent - a historical look at Decentralized Trials and their future with a focus on **eConsent**

Patients will be more empowered

- Trials will become decentralized
- Technology will support this decentralization:
  - Wearables
  - Telemedicine
  - **eConsent**

Neil Vivian, Senior Director of **Business Solutions and** Product Manager, Anju Software



Sales Enquiry Nicholas McCudden Head of Sponsorship Sales T: +44 (0)207 9472755 E: NicholasMcCudden@arenainternational.com

## **CASE STUDY** Stop taking the easy route! Delving into recent societal changes and how Clinical Trials can adapt

- Appreciating the need to be more inclusive with race but what about other underrepresented groups?
- Discussing the use of male vs female in ICFs and inclusion/exclusion criteria impact of not including LGBTQ+

12:15

12:45

- Exploring the benefits of updating your ICF to adapt to societal changes and linguistic challenges
- Best practices for engaging with ethics committees and coming to an agreement on
- Examples of getting wording approved by ethics committee get hands on today!

Laia Casas, Clinical Project Leader, Noucor Health SA

## **Explore how Barcelona Health Hub is pushing forward digital** tools in clinical trials

How does digital transformation happen?

- Discover how the health ecosystem looks like in 10 years from now
- Barcelona Health Hub and digital health as a solution
- How to choose a relevant partner for your clinical validation

Xavi Jofre, Digital Transformation Director. Barcelona Health Hub

### Exploring how to use data collected through consumerwearables and integrate them into a clinical trial

- How to integrate data collected through consumerwearables into a clinical trial
- Why consumer-wearables can provide wider access to clinical trials
- Consumer wearables and data that they can reliably collect
- Getting data from the wearables to contribute to the clinical trial

Ivanna Rosendal, Senior Director, IT Business Partner, Ascendis Pharma

## Leveraging local relationships for best in-country solutions to accelerate global drug development

- Partnering with a CRO to access European infrastructure, in depth local knowledge, site relationships and diverse patient populations
- Strategies to fast-track clinical trial start-up and patient recruitment timelines
- Are you ready for EU CTR? Challenges and lessons learned

David Chia, Senior Business Development Manager, Novotech

Development Manager,

## Simplifying site & patient engagement technology strategies through integration & automation

Technology strategies that reduce effort, cost & support sustainability goals

- Sites just want to get the job done Reduce the barrier to eClinical technology adoption at sites by offloading burden Not all technology,
- integration and automation strategies are the same Understand how best-inclass technologies. established integrations and seemless automation comes together to make a difference for sites, patients and sponsors
- How to evaluate technologies partners to maximize impact

## The Opportunities and Challenges of Moving to **Electronic Capture of** Informed Consent

Technology has revolutionized the process of obtaining a patient's informed consent to participate in a clinical trial. Benefits of electronic informed consent (eConsent) include increased security, speed of rollout, and detailed reporting in real time. However, concerns remain about the patient's experience with the informed consent process while they are being asked to make a serious decision about their own health. In this presentation, we will explore

- The advantages with eConsent for both patients and clinical site staff
- Potential user experience challenges

Diana Filipescu, Business

REGISTER **HERE** 

Sales Enquiry Nicholas McCudden Head of Sponsorship Sales T: +44 (0)207 9472755 E: NicholasMcCudden@arenainternational.com

#### EastHORN (A Novotech towards sustainability of consenting on a Company) goals digital device How the right technology The design-led investments and approach that YPrime automations can reduce has taken to its new carbon footprint and eConsent app optimize the clinical supply chain Karl McEvoy, Product Director, Kevin Landells, Vice President, Decentralised Trial Technology, Business Head of IRT, IQVIA **YPrime Technologies** Paul Margerison, Director, Karen Maduschke, Senior User Experience & Design Director and GM, Patient **YPrime** Consent, IQVIA Technologies 13:15 Lunch and networking Call for research in creative **Delving into Digital Health in** The Ecosystems Leaders climate in organization in **Oncology clinical trials** Mindset in Healthcare clinical development How can Digital health Discussing how solutions benefit oncology companies will not Mariusz will explore his research clinical trials compete against and discovery on how to help What digital health solution companies anymore. CRO and pharma to be more inclusion means for Ecosystems will productive sponsors, investigators, compete against solution providers and trial Ecosystems. You have participants to build ecosystems to Mariusz Olejniczak, CEO, WPD What do we need to do to win. 14:15 **Pharmaceuticlas** make this inclusion, standard Discovering the power of of practice ecosystems to create disruptive and innovative Caoimhe Vallely-Gilroy. value proposition Independent Advisor - HIRANI, Uncovering the former Global Head of Digital leadership mindset Health & Therapeutics at needed to work in Healthcare Business ecosystems: Moving from EGO to **ECOsystems** Orlando Vergara, Barcelona Health Hub Ambassador, former Novartis Neuroscience Head **Controlling Drug Supply Risk** Running Up That Hill: Accelerated performance of by Enabling Complex Protocols complex exploratory patient Accelerate Cycle Times & **Through Modern RTSM Support** studies: practical insights from Reach Patients Faster with investigational site elluminate 14:45 In today's clinical trial landscape, Operational oversight within Unique model of dedicated oversight and risk management outsourced models has research clinics in Eastern are essential for ensuring patient become increasingly complex Europe safety and regulatory compliance. for teams who are tasked with However, controlling these risks is managing trials amid a rapidly



Sales Enquiry
Nicholas McCudden
Head of Sponsorship Sales
T: +44 (0)207 9472755
E: NicholasMcCudden@arenainternational.com

not without its challenges. From demand/supply planning issues to forecasting inaccuracies, drug supply management can be a daunting task, especially with rising complexity in the protocol development process. So, how can we best enable this rising protocol complexity while controlling end-to-end drug supply risk for your studies?

Join this session to explore how these challenges can be addressed through modern Randomization and Trial Supply Management (RTSM) software. We will examine how advanced RTSM systems can be implemented for complex protocols without the need for lengthy implementation timelines. We will also discuss how modern RTSM forecasting/resupply algorithms can work to control drug supply risks in complex protocols. Finally, we'll consider how modern RTSM systems can combine the features highlighted above with providing flexible and prompt post go-live support through extensive self-service trial management capabilities

Benjamin Etschmann, Senior Forecasting Services Lead, 4G Clinical

- Strategies for fast patient enrollment and retention
- Operational tips for flawless study conduct
- Takeaways after operating under unprecedented circumstances / case studies

**Dr. Claudia Hesselmann,**Founder and CEO, **ARENSIA Exploratory Medicine** 

changing landscape of partners, technologies, and global regulations. Data proliferation along with dwindling resources has made it a top priority for clinical development teams to look to technology to improve cycle times and the overall experiences of data managers, medical monitors, and clinical operations leaders.

This presentation will highlight how the elluminate Clinical Data Cloud and Biometrics Services can reshape your data architecture by automating data flows to keep up with the pace of data evolution and speed time to insights

Learn how elluminate and eClinical's Biometrics Services deliver:

- Operational insights across numerous data sources that provides definitive answers and analytics on enrollment, protocol compliance and safety
- Improved study oversight with a holistic view of risk across all data sources
- 50 out-of-the-box visualizations to support supports cross-study analysis for deeper insights with self-service access to clinical and operational analytics
- Increased productivity across data management, medical monitoring, clinical operations, clinical programming and statistical analysis roles

Jason Konn, Solution
Consultant, eClinical Solutions



1						
				Tech Showcase – Clario		
S. Moo		Optimizing oversight & governance: What does oversight mean to you?	2023 UPDATE: Sharing practical experiences with Decentralized & Hybrid Trials – is there a future for DCT?	Communication & Innovation: Defining innovation in clinical trials		
	15:15	<ul> <li>Best practices and tools for managing supplier governance and ascertaining who is accountable</li> <li>Identifying the criteria to determine level of oversight needed for a vendor</li> <li>Local vendor oversight vs global provider oversight – how would you manage this differently?</li> <li>Strategies for managing CRO governance for small/start-up companies with limited resources or large companies with competing priorities</li> <li>Daniel McVeigh, Director, Clinical Project Lead, Alexion</li> </ul>	<ul> <li>Advantages of DCT; from taking the trial to the patient boosting recruitment</li> <li>The benefits and constraints of DCT based on practical experience from running DCT</li> <li>Learnings from an inspection of an interventional DCT - what is the role of the patient?</li> <li>Strategy/Planning: How do you make the decision to run a DCT; what are the considerations?</li> <li>Is the future hybrid trials as they are more realistic and practical compared to full DCT?</li> <li>John Zibert, Chief Medical Officer, Coegin Pharma AB</li> </ul>	<ul> <li>What is innovation in clinical trials?</li> <li>Why communication is key in our innovation strategy?</li> <li>How do we communicate innovation?</li> <li>Laura Jiménez Robledo, Clinical Project and Innovation Manager, Novo Nordisk</li> </ul>		
	15:45	Afternoon refreshments and networking				
	16:15	Pro et contra of working with Professional Site Networks for sponsors and CROs  • Does the industry needs professionalization of clinical research sites? • The general perception of site networks and site management organizations • What benefits can professional site networks provide to sponsors and CROs • Risks and drawbacks of working with Professional Site Networks	Paediatric-centric clinical trials: A right for children and young people  Children's rights in their involvement in clinical research Why? Who? Where? Involve children and young people Return on the investment and return on the engagement eYPAGnet: European Network of Young Person's Advisory Groups Network Case study: DCT in paediatric clinical trials  Begoña Nafria Escalera, Patient Engagement & Research Coordinator, Sant Joan de Deu Barcelona Hospital Joana Claverol, Clinical Research Unit Manager, Sant Joan de Deu Barcelona Hospital			



Sales Enquiry
Nicholas McCudden
Head of Sponsorship Sales
T: +44 (0)207 9472755
E: NicholasMcCudden@arenainternational.com

Ivan Vyshnyvetskyy, President, Ukrainian Association for Clinical Research

IND Versus CTA Submissions: Is Your Drug Development Program Ready to Take on Both?

Submitting an Investigational New Drug Application (IND) in the US and a Clinical Trial Application (CTA) in the EU are important milestones in new drug development, marking the transition from bench research to clinical studies in human participants. Successful IND and CTA submissions require careful planning and strict compliance with regulatory requirements, which can be especially challenging for first-time applicants.

This presentation will cover:

16:45

- An introduction to the IND, including the document structure, optimal data to include, and timeline considerations
- Key differences in the IND and CTA submission process, and how to leverage similarities in your drug development program
- The impact of the new, centralized EU trial regulation in global drug regulations

**Federica Martini,** Ph. D. Associate Director, Regulatory Affairs, **Premier Consulting**  Session Reserved for THREAD

REGISTER HERE

Sales Enquiry
Nicholas McCudden
Head of Sponsorship Sales
T: +44 (0)207 9472755
E: NicholasMcCudden@arenainternational.com

#### **CLOSING KEYNOTE**

Gain a comprehensive overview of the EU Clinical Trial Regulation and changes for trials in the EU

- Intro to EuCTR and CTIS
- Experience in CTIS and KPIs: Organization model Sponsor-CRO: Challenges and Success cases
- Benefits of submitting through the same portal for all sponsors/CROs and the advantages for biopharma companies of standardized timelines

17:15

- Overview of major new requirements, such as transparency rules and regulatory submission packages
- Understanding the new trial authorization process for regulatory and ethical approval

Lidya Domínguez, Clinical Research Manager, Sermes CRO Raquel Reviejo, Raquel Reviejo, EU Regional Submission Lead, MSD, Sermes CRO

17:55 Chair's Summary & Drinks Reception

#### **CLOSING KEYNOTE**

Decentralized Clinical Trials/Hybrid Trials: Lessons learned and what you need to know to run them successfully

- Delving into the promise of DCT
- Laying the innovation and technical foundation for DCT
- My key learnings from running DCT/hybrid trials
- Tangible takeaways

**Stephen Lutsch,** Former Director - Revolutionize Clinical Trials (ReCT), **LEO Pharma** 



# DAY TWO - THURSDAY 4TH MAY 2023

08:10	Registration and refreshments
08:45	Chair's opening remarks



Sales Enquiry
Nicholas McCudden
Head of Sponsorship Sales
T: +44 (0)207 9472755
E: NicholasMcCudden@arenainternational.com

#### Stream A:

Outsourcing & Clinical Operations
Chair: Werner Gladdines, VP, Clinical
Development Operations, Immunic
Therapeutics

#### Stream B:

Clinical Technology & Innovation
Chair: Priya Nair, Senior Analyst, GlobalData

#### PANEL DISCUSSION



09:00

Reversing the Conversation: What the clinical trial industry really wants from its service providers

We've all had to sit through pitches from vendor companies telling us what they can do for us, but now it's time to reverse the conversation! Hear from the trial industry as they discuss the services they would like to see from their solution providers, including:

- What they like to see in an outsourced partner organization
- What they would like a partner to know about them / how they work
- What things do they need a partner to do and what they don't need!
- What things can be best done in house?

Moderator: Werner Gladdines, VP, Clinical Development Operations, Immunic

**Therapeutics** 

Panellists: Sonja Weiser, Senior Director

Clinical Operations, Insmed;

Daniel McVeigh, Director, Clinical Project Lead,

Alexion;

Michael Zörer, Head of Clinical Operations,

#### WORKSHOP

# Introducing The Patient Centric Sample Interest Group

This workshop will explore different approaches and strategies for putting patients at the centre when collecting samples for clinical trials

James Rudge, Technical Director, Trajan Scientific and Medical

# EU MDR: how attractive is Europe for innovation?

Talking Points: "The aim of the presentation is to highlight MDR positive and negative consequences on the development of new medical devices by answering to the following questions:

- What are the main regulatory challenges for new medical devices after EU MDR?
- How MedTech companies are reacting?
- Is CE-mark still "first choice" by start-ups and SMEs?

Enrico Perfler, CEO, 1Med

Practical innovation: Powering IRT for improved patient management and drug logistics in a clinical trials platform

- Clinical trials today are becoming increasingly complex, and the technology landscape to manage them can be complicated and overwhelming.
- Seamlessly connecting IRT with eConsent and eCOA in a single platform enhances the user experience, reduces workloads, and drives rapid deployment through centrally shared data and streamlined workflows.
- Explore examples of how interoperable systems increase visibility to patient data, more accurately project supply and resupply needs, and support timely outcomes data collection, all through your IRT.

Marcel Besier, Senior Director, Services Delivery, Suvoda



Sales Enquiry
Nicholas McCudden
Head of Sponsorship Sales
T: +44 (0)207 9472755
E: NicholasMcCudden@arenainternational.com

Speaker Enquiry
Maya Hudson
Senior Conference Producer
E: maya.hudson@arenainternational.com

09:45

		Daniela Duffett, Solutions Consultant, Suvoda	
10:15	Establishing strong CRO/sponsor relationships and building trust in a more virtual landscape- What 5 things does our expert speaker say to focus on right now?  • Oversight with less presence- designing an oversight plan based on KPIs, fewer monitoring visits and more virtual meetings, how to make this work  • Lessons learned on how to effectively build working relationships remotely  • Strategies to deliver training and upskill your clinical trial team  • Handling hard discussions with the site remotely if can't get there in person  • Guidance on improving CRO communication channels- keep CROs in the loop and draw on their experience  • We are all human, we all fail: Ensuring positivity in initial stages and taking responsibility  Moderator: Werner Gladdines, VP, Clinical Development Operations, Immunic  Therapeutics  Marco Salami, Head of Clinical & RWE	The metaverse in Pharma it could be a possible solution?  • Explore what's the metaverse • If the pharma industry is ready for the tech • What could be an add value for the Customer  Stefania Alvino, Digital Orchestrator & Omnichannel Marketing Manager, Daiichi Sankyo	
10:45	How to succeed in your Oncology clinical trial from regional-medium CRO's point of view?  What is the added value of the small and medium CROs?  Can these CROs successfully manage current changes in technology paradigm?  Can we help to optimize enrollment challenge to reduce costs and get results within timelines?  Ana Moreno, Director Global Clinical Operations, APICES	Advancing Towards Patient-Centered Measurement Methods by Integrating ePRO in Oncology Trials; Lessons Learned from a Recent Study  Reviewing the strategy for the provision of the user-friendly platforms Identifying the potential barriers in day-to-day utilization and how they can be overcome Discussing the expectations of PRO in oncology research moving forward  Edyta Korzuch, Senior Director, Project Management, Oncology, TFS HealthScience	
11:15	Morning refreshments and networking		
11:45	Being a Process Manager, when all processes collapse – War in Ukraine, one sponsor's perspective	Bridging the gap from RCTs through Real World Evidence into clinical practice; exploring how to improve patient focussed disease management	



Sales Enquiry
Nicholas McCudden
Head of Sponsorship Sales
T: +44 (0)207 9472755
E: NicholasMcCudden@arenainternational.com

- What is business continuity during the war in Ukraine and how are we ensuring it?
- Leading people, process, projects
- Processes adaptation, flexible decisions: remote SDR and SDV implementation, electronic signatures
- Experience in patients transfers within and outside of Ukraine

Kateryna Orlovska, Country Clinical Quality Management Lead Ukraine, Georgia and CIS, Merck

- Relevance of generating Real World Evidence data in rare ad orphan kidney diseases
- The urgent need to access main clinical data, including those from still unpublished clinical studies
- Bridging an existing gap between randomized clinical trials results and clinical practice evidence for people affected by rare and orphan kidney diseases
- Development of 'personalized' treatment algorithms to improve patient-focused outcomes in patients suffering from these diseases

**Domenico Merante**, Therapeutic Area Clinical Lead Nephrology, Rare and Orphan Diseases, **CSL Vifor** 

Henrik Schou, VP, Global Head Evidence Generation, CSL Vifor

# Why Patient Participation Isn't Recovering and Tactics to Drive Change

- Covid-19 pandemic has changed the paradigm of clinical research, with a rapid uptick in adoption of new technologies and integrated ecosystems, to enable and support decentralized trials, patient recruitment and retention, or data transference form electronic health records (EHC) into electronic data capture (EDC), among others
- This new technologically-driven environment requires additional collaboration between Sponsors, Clinical Research Organizations (CRO), investigators and other vendors and providers.
- In parallel, global analysis shows a trend on decreasing number of subjects participating in clinical trials, as well as recruitment rates
- Is it time to look into clinical trials from a different angle?

Esther Mahillo PhD, Vice President, Operational Strategy, Precision Medicine

Exploring the role of Quality in vendor oversight and vendor quality agreements

 How can Quality provide more support to the study team, particularly with vendor oversight?

# Embedding patient recruitment into healthcare systems

As the UK's leading health tech supplier, we're connecting study sponsors and clinical research organisations with our vast network of healthcare professionals and patients to source quality clinical trial candidates at speed. Join this session to learn more about our Recruit solution, including:

- How we're enabling primary care organisations to get involved in patient recruitment for clinical trials
- How we're empowering participants to take part in clinical research by contacting them through trusted sources
- How we're making it easier for study sites to review and contact potentially eligible participants

Mihad Mohamed, Head of Product Management – Research and Life Sciences, EMIS

# Case study: Clinical digitalization roadmap for medical device companies

Outlining the specific digital transformation goals and requirements



Sales Enquiry
Nicholas McCudden
Head of Sponsorship Sales
T: +44 (0)207 9472755
E: NicholasMcCudden@arenainternational.com

Speaker Enquiry
Maya Hudson
Senior Conference Producer
E: maya.hudson@arenainternational.com

12:15

12:45

- Exploring the importance of quality agreements and vendor communications

   how can we add more value with monitoring/safety aspects?
- Best practices in reporting to ensure patience safety and preventative action
- How can Quality work more closely with regulatory bodies on reporting issues to ensure GCP?
- Exploring risk-based quality management strategies

Silvia Perez Torres, Director, Clinical Quality Compliance, Astrazeneca

 Overcoming operational challenges associated with medium-sized medical device companies

Journey to successful clinical digitalization

Balint Feher, Senior Clinical Research Manager, Geistlich Pharma AG

13:15 | Lunch and networking and Apple Prize draw

# Is a clinical trial a customer experience? Insights from consumer research

- Consumer brands thrive on a sophisticated understanding of the needs and motivations of their customers, and the role the brand plays in their lives.
- Clinical trials don't typically prioritise such a deep understanding of their end user, but trials don't happen in a vacuum.
- As people increasingly expect consumerlike personalisation and choice from their healthcare, what can clinical trials learn from thinking of participants as customers?

Harry Yeates, Strategy Director, Langland Advertising & Marketing Ltd

# Practical use cases to improve clinical site efficiency with technology

- Using technology to work with sites
- Using machine learning to increase efficiency
- Leveraging interoperability to streamline operations

Jay Smith, Head of Product, Trial Interactive, TransPerfect

## The current impact and future of Decentralized Clinical Trials

14:45

14:15

- The impact of COVID-19 on the future of clinical trials and the main concern for primary sponsors and CRO's during the COVID-19 pandemic
- The movement towards DCT's and why sponsors are incorporating digital elements into clinical trials and the challenges around this
- How AI can aid decentralized trials and real-life case studies

Priya Nair, Senior Analyst, GlobalData

### 15:15 INTERACTIVE THINK TANKS



Interactive think tank sessions offer a unique opportunity to come together to share best practice and develop solutions to challenges facing the industry as a whole. Hosted by industry experts and each focused on a single issue, think tanks are an interactive way to build your personal network and learn from the experience of others.

Each think tank session lasts for 30 minutes, and delegates may attend up to 2

Think Tank 1: What does the clinical trial industry really want from its service providers? Host: Estrella Garcia, Senior Director Global Clinical Operations, Almirall



Sales Enquiry
Nicholas McCudden
Head of Sponsorship Sales
T: +44 (0)207 9472755
E: NicholasMcCudden@arenainternational.com

Think Tank 2: Building strategic partnerships with CROs
Host: Elena Carzana, Vendors Alliance Manager DM&Stat, Chiesi Farmaceutici
& Anna Pugnetti, Global Clinical and RWE Outsourcing Manager, Chiesi Farmaceutici

Think Tank 3: Communication & Innovation: Defining innovation in clinical trials
Laura Jiménez Robledo, Clinical Project and Innovation Manager, Novo Nordisk

Think Tank 4: Fighting the System: A Provocative Discussion on Challenging the Flaws and
Injustices of the Clinical Trials Industry for Better Results
Ivan Vyshnyvetskyy, - President of the Ukrainian Association for Clinical Research, Managing Director
Ukraine at FutureMeds

16:15 End of Event